1-[[4-[(1R,5S)-8-azabicyclo[3.2.1]octan-8-yl]-3,5-difluorophenyl]methyl]-3-(1H-indazol-4-yl)urea
C22H23F2N5O — CID 16748373
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[[4-[(1R,5S)-8-azabicyclo[3.2.1]octan-8-yl]-3,5-difluorophenyl]methyl]-3-(1H-indazol-4-yl)urea
1-[[4-[(1R,5S)-8-azabicyclo[3.2.1]octan-8-yl]-3,5-difluorophenyl]methyl]-3-(1H-indazol-4-yl)urea (PubChem CID 16748373) has the molecular formula C22H23F2N5O and a molecular weight of 411.46 g/mol. Its IUPAC name is 1-[[4-[(1R,5S)-8-azabicyclo[3.2.1]octan-8-yl]-3,5-difluorophenyl]methyl]-3-(1H-indazol-4-yl)urea.
Molecular Properties
| Compound Name | 1-[[4-[(1R,5S)-8-azabicyclo[3.2.1]octan-8-yl]-3,5-difluorophenyl]methyl]-3-(1H-indazol-4-yl)urea |
|---|---|
| PubChem CID | 16748373 |
| Molecular Formula | C22H23F2N5O |
| Molecular Weight | 411.46 g/mol |
| Exact Mass | 411.19 |
| IUPAC Name | 1-[[4-[(1R,5S)-8-azabicyclo[3.2.1]octan-8-yl]-3,5-difluorophenyl]methyl]-3-(1H-indazol-4-yl)urea |
| SMILES | O=C(NCc1cc(F)c(N2[C@@H]3CCC[C@H]2CC3)c(F)c1)Nc1cccc2[nH]ncc12 |
| InChI | InChI=1S/C22H23F2N5O/c23-17-9-13(10-18(24)21(17)29-14-3-1-4-15(29)8-7-14)11-25-22(30)27-19-5-2-6-20-16(19)12-26-28-20/h2,5-6,9-10,12,14-15H,1,3-4,7-8,11H2,(H,26,28)(H2,25,27,30)/t14-,15+ |
| InChIKey | FPQHPUDYHCLCTO-GASCZTMLSA-N |
| XLogP | 4.68 |
| TPSA | 73.05 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 411.46 |
| LogP ≤ 5 | 4.68 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 3 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 16748373 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.